# Xenetic Biosciences, Inc.: overview XBIO · Nasdaq · CIK 1534525 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xbio.md) · [Financials](/companies/xbio/financials.md) · [Filings](/companies/xbio/filings.md) · [Insiders](/companies/xbio/insiders.md) Latest reported revenue: [$660.6k](/filings/0001683168-26-006061.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-006061). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [614](/filings/0001683168-25-008259.md) | [649 d](/filings/0001683168-26-001737.md) | [593](/filings/0001683168-26-003727.md) | [590](/filings/0001683168-26-006061.md) | [1,027](/filings/0001683168-25-008259.md) | [766 d](/filings/0001683168-26-001737.md) | [807](/filings/0001683168-26-003727.md) | [661](/filings/0001683168-26-006061.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(81.3%)](/filings/0001683168-25-008259.md) | [(169.4%) d](/filings/0001683168-26-001737.md) | [(158.9%)](/filings/0001683168-26-003727.md) | [(122.8%)](/filings/0001683168-26-006061.md) | [(53.0%)](/filings/0001683168-25-008259.md) | [(81.3%) d](/filings/0001683168-26-001737.md) | [(62.2%)](/filings/0001683168-26-003727.md) | [(147.1%)](/filings/0001683168-26-006061.md) | | Net margin | % | [(71.1%)](/filings/0001683168-25-008259.md) | [(162.5%) d](/filings/0001683168-26-001737.md) | [(152.2%)](/filings/0001683168-26-003727.md) | [(116.7%)](/filings/0001683168-26-006061.md) | [(49.7%)](/filings/0001683168-25-008259.md) | [(75.6%) d](/filings/0001683168-26-001737.md) | [(56.6%)](/filings/0001683168-26-003727.md) | [(140.7%)](/filings/0001683168-26-006061.md) | | Diluted EPS | $ per share | [(0.28)](/filings/0001683168-25-008259.md) | not reported | [(0.59)](/filings/0001683168-26-003727.md) | [(0.45)](/filings/0001683168-26-006061.md) | [(0.33)](/filings/0001683168-25-008259.md) | not reported | [(0.20)](/filings/0001683168-26-003727.md) | [(0.41)](/filings/0001683168-26-006061.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,161](/filings/0001683168-23-001674.md) | [1,707](/filings/0001683168-24-001594.md) | [2,540](/filings/0001683168-25-001686.md) | [2,500](/filings/0001683168-26-001737.md) | [2,976](/filings/0001683168-26-001737.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(495.1%)](/filings/0001683168-23-001674.md) | [(393.6%)](/filings/0001683168-24-001594.md) | [(177.8%)](/filings/0001683168-25-001686.md) | [(168.2%)](/filings/0001683168-26-001737.md) | [(95.2%)](/filings/0001683168-26-001737.md) | | Net margin | % | [(486.4%)](/filings/0001683168-23-001674.md) | [(383.9%)](/filings/0001683168-24-001594.md) | [(162.8%)](/filings/0001683168-25-001686.md) | [(158.4%)](/filings/0001683168-26-001737.md) | [(90.1%)](/filings/0001683168-26-001737.md) | | Diluted EPS | $ per share | [(0.55)](/filings/0001683168-23-001674.md) | [(4.61)](/filings/0001683168-24-001594.md) | [(2.71)](/filings/0001683168-25-001686.md) | [(2.57)](/filings/0001683168-26-001737.md) | [(1.58)](/filings/0001683168-26-001737.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xbio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $341.8k | 117,440 | | Reduced −20,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $50.7k | 17,423 | | Reduced −4,018 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $36.9k | 12,681 | | Added +5,950 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $2.9k | 1,000 | | New +1,000 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.0k | 696 | | Reduced −110 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $437 | 150 | | New +150 | | [JTC Employer Solutions Trustee Ltd](/funds/1875645.md) | 2026-06-30 | $8 | 2,700 | | Unchanged | | [Darwin Wealth Management, LLC](/funds/1663224.md) | 2026-06-30 | $5 | 2 | | Unchanged | ## Recent filings [All 482 filings](/companies/xbio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-23 | 17:20 ET | [8-K](/filings/0001683168-26-007340.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-007340 | | 2026-09-16 | 07:00 ET | [8-K](/filings/0001683168-26-007181.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-007181 | | 2026-08-07 | 08:35 ET | [8-K](/filings/0001683168-26-006077.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-006077 | | 2026-08-06 | 16:30 ET | [10-Q](/filings/0001683168-26-006061.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006061 | | 2026-05-13 | 08:05 ET | [8-K](/filings/0001683168-26-003766.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-003766 | | 2026-05-12 | 16:30 ET | [10-Q](/filings/0001683168-26-003727.md) | Quarterly report, period 2026-03-31 | 0001683168-26-003727 | | 2026-04-24 | 17:15 ET | [10-K/A](/filings/0001683168-26-003207.md) | Annual report, amended, period 2025-12-31 | 0001683168-26-003207 | | 2026-04-24 | 17:00 ET | [8-K](/filings/0001683168-26-003203.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-003203 | | 2026-03-13 | 08:00 ET | [8-K](/filings/0001683168-26-001744.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-001744 | | 2026-03-12 | 17:00 ET | [10-K](/filings/0001683168-26-001737.md) | Annual report, period 2025-12-31 | 0001683168-26-001737 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-001737.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0f3574cd-0316-4f1f-8b4e-b183fe651600) ## About the filer - CIK: 1534525 - Tickers: XBIO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.